|Articles|January 11, 2022
- Pharmaceutical Executive-01-01-2022
- Volume 42
- Issue 1
Pharmaceutical Executive, January 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive January 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 4 years ago
Keeping Tabs on Quality: The Rise of Digitalover 4 years ago
China Invests in Building Biotechover 4 years ago
Branding Takes on a New Lookover 4 years ago
Addressing Access Burdensover 4 years ago
Meeting the Patient—Virtuallyover 4 years ago
The Age of Influenceover 4 years ago
Boosting Immunotherapiesover 4 years ago
Pharma’s Psychedelic Experienceover 4 years ago
Supply Chain Procurementover 4 years ago
Our View on 2022: Pharm Exec’s Annual Industry OutlookNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals
2
Travere Therapeutics’ Filspari Receives Full FDA Approval
3
Managing Patient Experience and RWE in Clinical Trials: Q&A with Matt Holms, MB
4
FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment
5

